{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:12:22Z","timestamp":1769760742282,"version":"3.49.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1993,2,1]],"date-time":"1993-02-01T00:00:00Z","timestamp":728524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1993,2,1]],"date-time":"1993-02-01T00:00:00Z","timestamp":728524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm Gen Sect"],"published-print":{"date-parts":[[1993,2]]},"DOI":"10.1007\/bf02252624","type":"journal-article","created":{"date-parts":[[2005,11,22]],"date-time":"2005-11-22T14:44:08Z","timestamp":1132670648000},"page":"63-72","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Glutamate receptor antagonists for neuroleptic malignant syndrome and akitetic hyperthermic Parkinsonian crisis"],"prefix":"10.1007","volume":"6","author":[{"given":"J.","family":"Kornhuber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Weller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Riederer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[1993,4,1]]},"reference":[{"key":"BF02252624_CR1","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/0006-3223(87)90010-2","volume":"22","author":"G Addonizio","year":"1987","unstructured":"Addonizio G, Susman VL, Roth SD (1987) Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 22: 1004\u20131020","journal-title":"Biol Psychiatry"},{"key":"BF02252624_CR2","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","volume":"12","author":"RL Albin","year":"1989","unstructured":"Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366\u2013375","journal-title":"Trends Neurosci"},{"key":"BF02252624_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/archneur.1971.00480310078007","volume":"24","author":"O Appenzeller","year":"1971","unstructured":"Appenzeller O, Goss JE, Albuquerque NM (1971) Autonomic deficits in Parkinson's disease. Arch Neurol 24: 50\u201357","journal-title":"Arch Neurol"},{"key":"BF02252624_CR4","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1212\/WNL.40.11.1797","volume":"40","author":"L Baca","year":"1990","unstructured":"Baca L, Martinelli L (1990) Neuroleptic malignant syndrome: a unique association with a tricyclic antidepressant. Neurology 40: 1797\u20131798","journal-title":"Neurology"},{"key":"BF02252624_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0006-8993(91)90871-R","volume":"555","author":"MK Bazil","year":"1991","unstructured":"Bazil MK, Gordon FJ (1991) Effect of blockade of spinal NMDA receptors on sympathoexcitation and cardiovascular responses produced by cerebral ischemia. Brain Res 555: 149\u2013152","journal-title":"Brain Res"},{"key":"BF02252624_CR6","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1126\/science.2402638","volume":"244","author":"H Bergman","year":"1990","unstructured":"Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 244: 1436\u20131438","journal-title":"Science"},{"key":"BF02252624_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-7091-2253-2","volume-title":"Die Parkinson-Krankheit. Biochemie, Klinik, Therapie","author":"W Birkmayer","year":"1980","unstructured":"Birkmayer W, Riederer P (1980) Die Parkinson-Krankheit. Biochemie, Klinik, Therapie. Springer, Wien New York, pp 83\u201387"},{"key":"BF02252624_CR8","first-page":"35","volume":"27","author":"S Bittkau","year":"1988","unstructured":"Bittkau S, Przuntek H (1988) Chronic s. c. lisuride in Parkinson's disease \u2014 motorper-formance and avoidance of psychiatric side effects. J Neural Transm [Suppl] 27: 35\u201354","journal-title":"J Neural Transm [Suppl]"},{"key":"BF02252624_CR9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/0014-2999(89)90385-3","volume":"166","author":"J Bormann","year":"1989","unstructured":"Bormann J (1989) Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 166: 591\u2013592","journal-title":"Eur J Pharmacol"},{"key":"BF02252624_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1476-5381.1976.tb08624.x","volume":"58","author":"F Brown","year":"1976","unstructured":"Brown F, Redfern PH (1976) Studies on the mechanism of action of amantadine. Br J Pharmacol 58: 561\u2013567","journal-title":"Br J Pharmacol"},{"key":"BF02252624_CR11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/jcbfm.1991.53","volume":"11","author":"T Br\u00fccke","year":"1991","unstructured":"Br\u00fccke T, Podreka I, Angelberger P, Wenger S, Topitz A, K\u00fcfferle B, M\u00fcller C, Deecke L (1991) Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 11: 220\u2013228","journal-title":"J Cereb Blood Flow Metab"},{"key":"BF02252624_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/0140-6736(92)91108-K","volume":"339","author":"T Br\u00fccke","year":"1992","unstructured":"Br\u00fccke T, Roth J, Podreka I, Strobl R, Wenger S, Asenbaum S (1992) Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics. Lancet 339: 497","journal-title":"Lancet"},{"key":"BF02252624_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1523\/JNEUROSCI.10-01-00311.1990","volume":"10","author":"A Buchan","year":"1990","unstructured":"Buchan A, Pulsinelli WA (1990) Hypothermia but not N-methyl-D-aspartate antagonist, MK-801, attenuates neuronal damage in gerbils subjected to transient global ischemia. J Neurosci 10: 311\u2013316","journal-title":"J Neurosci"},{"key":"BF02252624_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/BF01258633","volume":"75","author":"M Carlsson","year":"1989","unstructured":"Carlsson M, Carlsson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75: 221\u2013226","journal-title":"J Neural Transm"},{"key":"BF02252624_CR15","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1523\/JNEUROSCI.12-11-04427.1992","volume":"12","author":"HSV Chen","year":"1992","unstructured":"Chen HSV, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA (1992) Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 12: 4427\u20134436","journal-title":"J Neurosci"},{"key":"BF02252624_CR16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/0006-8993(90)91424-F","volume":"514","author":"D Corbett","year":"1990","unstructured":"Corbett D, Evans S, Thomas C, Wang D, Jonas RA (1990) MK-801 reduced cerebral ischemic injury by inducing hypothermia. Brain Res 514: 300\u2013304","journal-title":"Brain Res"},{"key":"BF02252624_CR17","first-page":"1278","volume":"24","author":"W Danielczyk","year":"1973","unstructured":"Danielczyk W (1973) Die Behandlung von akinetischen Krisen. Med Welt 24: 1278\u20131282","journal-title":"Med Welt"},{"key":"BF02252624_CR18","first-page":"211","volume":"3","author":"AE DiRosa","year":"1988","unstructured":"DiRosa AE, Morgante L, Coraci MA, Crisafulli A, Cacciola G, DiStefano G, Meduri M, DiPerri R (1988) Functional hyperthermia due to central dopaminergic impairment. Funct Neurol 3: 211\u2013215","journal-title":"Funct Neurol"},{"key":"BF02252624_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00735871","volume":"94","author":"L Farde","year":"1988","unstructured":"Farde L, Wiesel F-A, Jansson P, Uppfeldt G, Wahlen A, Sedvall G (1988) An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor accupancy by PET. Psychopharmacology 94: 1\u20137","journal-title":"Psychopharmacology"},{"key":"BF02252624_CR20","first-page":"119","volume-title":"Vegetativst\u00f6rungen beim Parkinson-Syndrom","author":"F Gerstenbrand","year":"1984","unstructured":"Gerstenbrand F, Poewe W (1984) St\u00f6rungen der Thermoregulation beim Parkinson-Syndrom. In: Fischer PA (Hrsg) Vegetativst\u00f6rungen beim Parkinson-Syndrom. Editiones \u00abRoche\u00bb, Basel, S. 119\u2013125"},{"key":"BF02252624_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/0014-2999(85)90564-3","volume":"110","author":"G Gianutsos","year":"1985","unstructured":"Gianutsos G, Chute S, Dunn JP (1985) Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol 110: 357\u2013361","journal-title":"Eur J Pharmacol"},{"key":"BF02252624_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1212\/WNL.36.1.73","volume":"36","author":"CG Goetz","year":"1986","unstructured":"Goetz CG, Lutge W, Tanner CM (1986) Autonomic dysfunctions in Parkinson's disease. Neurology 36: 73\u201375","journal-title":"Neurology"},{"key":"BF02252624_CR23","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1056\/NEJM198006263022614","volume":"302","author":"DA Goodkin","year":"1980","unstructured":"Goodkin DA (1980) Mechanism of bromocriptine-induced hallucinations. N Engl J Med 302: 1479","journal-title":"N Engl J Med"},{"key":"BF02252624_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ana.410140117","volume":"14","author":"JE Granato","year":"1983","unstructured":"Granato JE, Stern BJ, Ringel A, et al (1983) Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine. Ann Neurol 14: 89\u201390","journal-title":"Ann Neurol"},{"key":"BF02252624_CR25","first-page":"679","volume":"16","author":"RJ Gruen","year":"1990","unstructured":"Gruen RJ, Roth RH, Bunney BS, Moghadam B (1990) Increase in striatal dopamine release following local perfusion of the NMDA receptor antagonist 2-amino-5-phosphonopentanoic acid. Soc Neurosci Abstr 16: 679","journal-title":"Soc Neurosci Abstr"},{"key":"BF02252624_CR26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/0006-3223(90)90485-K","volume":"28","author":"M Halman","year":"1990","unstructured":"Halman M, Goldbloom DS (1990) Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry 28: 518\u2013521","journal-title":"Biol Psychiatry"},{"key":"BF02252624_CR27","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/0010-440X(86)90002-7","volume":"27","author":"P Hamburg","year":"1986","unstructured":"Hamburg P, Weilburg JB, Cassem NH, Cohen L, Brown S (1986) Relapse of neuroleptic malignant syndrome with early discontinuation of amantadine therapy. Compr Psychiatry 27: 272\u2013275","journal-title":"Compr Psychiatry"},{"key":"BF02252624_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/00002826-198704000-00010","volume":"10","author":"M Harris","year":"1987","unstructured":"Harris M, Nora L, Tanner CM (1987) Neuroleptic malignant syndrome responsive to carbidopa\/levodopa: support of a dopaminergic hypothesis. Clin Neuropharmacol 10: 186\u2013189","journal-title":"Clin Neuropharmacol"},{"key":"BF02252624_CR29","first-page":"328","volume":"48","author":"HH Harsch","year":"1987","unstructured":"Harsch HH (1987) Neuroleptic malignant syndrome: physiological and laboratory findings in a series of nine cases. J Clin Psychiatry 48: 328\u2013333","journal-title":"J Clin Psychiatry"},{"key":"BF02252624_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/0014-2999(72)90144-6","volume":"20","author":"RE Heikkila","year":"1972","unstructured":"Heikkila RE, Cohen G (1972) Evaluation of amantadine as a releasing agent or uptake blocker for 3H-dopamine in rat brain slices. Eur J Pharmacol 20: 156\u2013160","journal-title":"Eur J Pharmacol"},{"key":"BF02252624_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1212\/WNL.31.2.132","volume":"31","author":"VW Henderson","year":"1981","unstructured":"Henderson VW, Wooten GF (1981) Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology 31: 132\u2013137","journal-title":"Neurology"},{"key":"BF02252624_CR32","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/0006-3223(89)90275-8","volume":"25","author":"H Hermesh","year":"1989","unstructured":"Hermesh H, Sirota P, Eviatar J (1989) Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine. Biol Psychiatry 25: 962\u2013965","journal-title":"Biol Psychiatry"},{"key":"BF02252624_CR33","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0014-2999(90)90387-L","volume":"187","author":"A Imperato","year":"1990","unstructured":"Imperato A, Scrocco MG, Bacchi S, Angelucci L (1990) NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur J Pharmacol 187: 555\u2013556","journal-title":"Eur J Pharmacol"},{"key":"BF02252624_CR34","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1097\/00007611-198612000-00022","volume":"79","author":"A Janati","year":"1986","unstructured":"Janati A, Webb RT (1986) Successful treatment of neuroleptic malignant syndrome with bromocriptine. South Med J 79: 1567\u20131571","journal-title":"South Med J"},{"key":"BF02252624_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0006-8993(91)90602-R","volume":"549","author":"M-C Kao","year":"1991","unstructured":"Kao M-C, Lee HK, Chai CY, Wang Y (1991) NMDA antagonists attenuate hypertension induced by carotid clamping in the rostral ventrolateral medulla of rats. Brain Res 549: 83\u201389","journal-title":"Brain Res"},{"key":"BF02252624_CR36","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/0014-2999(74)90292-1","volume":"28","author":"ME Karobath","year":"1974","unstructured":"Karobath ME (1974) Amantadine and D-145, an amantadine derivative, do not effect dopamine sensitive adenylate cyclase from the caudate-putamen of the rat brain. Eur J Pharmacol 28: 376\u2013378","journal-title":"Eur J Pharmacol"},{"key":"BF02252624_CR37","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/ana.410280411","volume":"28","author":"T Klockgether","year":"1990","unstructured":"Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions of L-DOPA in monoamine-depleted rats. Ann Neurol 28: 539\u2013546","journal-title":"Ann Neurol"},{"key":"BF02252624_CR38","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/ana.410300513","volume":"30","author":"T Klockgether","year":"1991","unstructured":"Klockgether T, Turski L, Honor\u00e9 T, Zhang Z, Gash DM, Kurlan R, Greenamyre JT (1991) The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 30: 717\u2013723","journal-title":"Ann Neurol"},{"key":"BF02252624_CR39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-3-7091-3330-9_4","volume-title":"Neuro-Psychopharmaka, Bd. 5","author":"J Kornhuber","year":"1992","unstructured":"Kornhuber J, Streifler M (1992) Adamantanamine. In: Riederer P, Laux G, P\u00f6ldinger W (Hrsg) Neuro-Psychopharmaka, Bd. 5. Springer, Wien New York, S. 59\u201376"},{"key":"BF02252624_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/BF01245162","volume":"92","author":"J Kornhuber","year":"1993","unstructured":"Kornhuber J, Weller M (1993) Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. J Neural Transm [Gen Sect] 92: 57\u201365","journal-title":"J Neural Transm [Gen Sect]"},{"key":"BF02252624_CR41","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0014-2999(89)90384-1","volume":"166","author":"J Kornhuber","year":"1989","unstructured":"Kornhuber J, Bormann J, Retz W, H\u00fcbers M, Riederer P (1989) Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166: 589\u2013590","journal-title":"Eur J Pharmacol"},{"key":"BF02252624_CR42","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0922-4106(91)90113-V","volume":"206","author":"J Kornhuber","year":"1991","unstructured":"Kornhuber J, Bormann J, H\u00fcbers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol [Mol Pharmacol Sect] 206: 297\u2013300","journal-title":"Eur J Pharmacol [Mol Pharmacol Sect]"},{"key":"BF02252624_CR43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00002826-198406000-00001","volume":"7","author":"R Kurlan","year":"1984","unstructured":"Kurlan R, Hamill R, Shoulson I (1984) Neuroleptic malignant syndrome. Clin Neuropharmacol 7: 109\u2013120","journal-title":"Clin Neuropharmacol"},{"key":"BF02252624_CR44","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1523\/JNEUROSCI.11-09-02931.1991","volume":"11","author":"YY Lai","year":"1991","unstructured":"Lai YY, Siegel JM (1991) Pontomedullary glutamate receptors mediating locomotion and muscle tone suppression. J Neurosci 11: 2931\u20132937","journal-title":"J Neurosci"},{"key":"BF02252624_CR45","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1176\/ajp.142.1.142a","volume":"142","author":"A Lazarus","year":"1985","unstructured":"Lazarus A (1985) Neuroleptic malignant syndrome and amantadine withdrawal. Am J Psychiatry 142: 142","journal-title":"Am J Psychiatry"},{"key":"BF02252624_CR46","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1161\/01.HYP.13.6.759","volume":"13","author":"SJ Lewis","year":"1989","unstructured":"Lewis SJ, Barres C, Jacob HJ, Ohta H, Brody MJ (1989) Cardiovascular effects of the N-methyl-D-aspartate receptor antagonist MK-801 in conscious rats. Hypertension 13: 759\u2013765","journal-title":"Hypertension"},{"key":"BF02252624_CR47","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0022-3565(25)10406-0","volume":"263","author":"A Lupp","year":"1992","unstructured":"Lupp A, L\u00fccking CH, Koch R, Jackisch R, Feuerstein TJ (1992) Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 263: 717\u2013724","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02252624_CR48","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/BF00403648","volume":"24","author":"J Maj","year":"1972","unstructured":"Maj J, Sowinska H, Baran L (1972) The effect of amantadine on motor activity and catalepsy in rats. Psychopharmacologia (Berl) 24: 296\u2013307","journal-title":"Psychopharmacologia (Berl)"},{"key":"BF02252624_CR49","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0304-3940(91)90599-O","volume":"131","author":"NB Mercuri","year":"1991","unstructured":"Mercuri NB, Stratta F, Calabresi P, Bernardi G (1991) Nomifensine but not amantadine increases dopamine-induced responses on rat substantia nigra zona compacta neurons. Neurosci Lett 131: 145\u2013148","journal-title":"Neurosci Lett"},{"key":"BF02252624_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-1838(91)90124-L","volume":"36","author":"M Miura","year":"1991","unstructured":"Miura M, Takayama K, Okada J (1991) Difference in sensitivity of cardiovascular and respiratory control neurons in the subretrofacial nucleus to glutamate receptor subtype agonists in SHR, WKY and cats. J Auton Nerv Syst 36: 1\u201312","journal-title":"J Auton Nerv Syst"},{"key":"BF02252624_CR51","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0014-2999(87)90123-3","volume":"142","author":"JW Olney","year":"1987","unstructured":"Olney JW, Price MT, Labruyere J, Salles KS, Frierdich G, Mueller M, Silverman E (1987) Anti-parkinsonian agents are phencyclidine agonists and N-methyl-aspartate antagonists. Eur J Pharmacol 142: 319\u2013320","journal-title":"Eur J Pharmacol"},{"key":"BF02252624_CR52","first-page":"1246","volume":"32","author":"NN Osborne","year":"1982","unstructured":"Osborne NN, Beale R, Golombiowska-Nikitin K, Sontag K-H (1982) The effect of memantine on various neurobiological processes. Arzneimittelforschung\/Drug Res 32: 1246\u20131255","journal-title":"Arzneimittelforschung\/Drug Res"},{"key":"BF02252624_CR53","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0028-3908(74)90009-4","volume":"13","author":"R Papeschi","year":"1974","unstructured":"Papeschi R (1974) Amantadine may stimulate dopamine and noradrenaline receptors. Neuropharmacology 13: 77\u201383","journal-title":"Neuropharmacology"},{"key":"BF02252624_CR54","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/NEJM197910183011606","volume":"301","author":"D Parkes","year":"1979","unstructured":"Parkes D (1979) Bromocriptine. N Engl J Med 301: 873\u2013878","journal-title":"N Engl J Med"},{"key":"BF02252624_CR55","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0140-6736(70)90634-3","volume":"i","author":"JD Parkes","year":"1970","unstructured":"Parkes JD, Zilkha KJ, Calver DM, Knill-Jones RP (1970) Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet i: 259\u2013262","journal-title":"Lancet"},{"key":"BF02252624_CR56","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/BF02260076","volume":"4","author":"JM Rabey","year":"1992","unstructured":"Rabey JM, Nissipeanu P, Korczyn AD (1992) Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm [PD-Sect] 4: 277\u2013282","journal-title":"J Neural Transm [PD-Sect]"},{"key":"BF02252624_CR57","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/j.1471-4159.1990.tb01943.x","volume":"54","author":"TS Rao","year":"1990","unstructured":"Rao TS, Kim HS, Lehmann J, Martin LL, Wood PL (1990) Interactions of phencyclidine receptor agonist MK-801 with dopaminergic system: regional studies in the rat. J Neurochem 54: 1157\u20131162","journal-title":"J Neurochem"},{"key":"BF02252624_CR58","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/mds.870050215","volume":"5","author":"ME Rodriguez","year":"1990","unstructured":"Rodriguez ME, Luquin MR, Lera G, Delgado G, Salazar JM, Obeso JA (1990) Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion. Mov Disord 5: 170\u2013172","journal-title":"Mov Disord"},{"key":"BF02252624_CR59","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1192\/bjp.159.5.709","volume":"159","author":"PI Rosebush","year":"1991","unstructured":"Rosebush PI, Stewart T, Mazurek MF (1991) The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry 159: 709\u2013712","journal-title":"Br J Psychiatry"},{"key":"BF02252624_CR60","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1001\/archinte.1989.00390090009002","volume":"149","author":"M Rosenberg","year":"1989","unstructured":"Rosenberg M, Green M (1989) Neuroleptic malignant syndrome: review of response to therapy. Arch Intern Med 149: 1927\u20131931","journal-title":"Arch Intern Med"},{"key":"BF02252624_CR61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3928\/0048-5713-19910301-08","volume":"21","author":"P Sakkas","year":"1991","unstructured":"Sakkas P, Davis JM, Hva J, Wang Z (1991) Pharmacotherapy of neuroleptic malignant syndrome. Psychiatr Ann 21: 9\u201314","journal-title":"Psychiatr Ann"},{"key":"BF02252624_CR62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0014-2999(70)90194-9","volume":"13","author":"B Scatton","year":"1970","unstructured":"Scatton B, Cheramy A, Besson MJ, Glowinski J (1970) Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. Eur J Pharmacol 13: 131\u2013133","journal-title":"Eur J Pharmacol"},{"key":"BF02252624_CR63","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/0091-3057(89)90007-5","volume":"32","author":"WJ Schmidt","year":"1989","unstructured":"Schmidt WJ, Bubser M (1989) Anti-cataleptic effects of the N-methyl-aspartate antagonist MK-801. Pharmacol Biochem Behav 32: 621\u2013623","journal-title":"Pharmacol Biochem Behav"},{"key":"BF02252624_CR64","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1001\/jama.1969.03160070046011","volume":"208","author":"RS Schwab","year":"1969","unstructured":"Schwab RS, England AC, Poskanzer DC, Young RR (1969) Amantadine in the treatment of Parkinson's disease. JAMA 208: 1168\u20131170","journal-title":"JAMA"},{"key":"BF02252624_CR65","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/00004714-199106000-00006","volume":"11","author":"B Sczesni","year":"1991","unstructured":"Sczesni B, Bittkau S, von Baumgarten F, von Schr\u00f6der J, Suchy I Przuntek H (1991) Intravenous lisuride in the treatment of the neuroleptic malignant syndrome. J Clin Psychopharmacol 11: 185\u2013188","journal-title":"J Clin Psychopharmacol"},{"key":"BF02252624_CR66","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1176\/ajp.141.6.796","volume":"141","author":"DM Simpson","year":"1984","unstructured":"Simpson DM, Davis GC (1984) Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine. Am J Psychiatry 141: 796\u2013797","journal-title":"Am J Psychiatry"},{"key":"BF02252624_CR67","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1176\/ajp.145.1.110","volume":"145","author":"A Shalev","year":"1988","unstructured":"Shalev A, Hermesh H, Munitz H (1988) The role of external heat load in triggering the neuroleptic malignant syndrome. Am J Psychiatry 145: 110\u2013111","journal-title":"Am J Psychiatry"},{"key":"BF02252624_CR68","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0304-3940(77)90181-1","volume":"4","author":"TW Stone","year":"1977","unstructured":"Stone TW (1977) Evidence for a non-dopaminergic action of amantadine. Neurosci Lett 4: 343\u2013346","journal-title":"Neurosci Lett"},{"key":"BF02252624_CR69","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/0014-2999(92)90634-G","volume":"213","author":"JC Stoof","year":"1992","unstructured":"Stoof JC, Booij J, Drukarch B, Wolters EC (1992) The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 213: 439\u2013443","journal-title":"Eur J Pharmacol"},{"key":"BF02252624_CR70","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2190\/LXD2-JTXJ-3LPQ-9PDN","volume":"14","author":"A Stoudemire","year":"1984","unstructured":"Stoudemire A, Luther JS (1984) Neuroleptic malignant syndrome and neuroleptic-induced catatonia: differential diagnosis and treatment. Int J Psychiatry Med 14: 57\u201363","journal-title":"Int J Psychiatry Med"},{"key":"BF02252624_CR71","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000120240","volume":"12","author":"M Tenenbein","year":"1985","unstructured":"Tenenbein M (1985) The neuroleptic malignant syndrome: occurrence in a 15-year-old boy and recovery with bromocriptine therapy. Pediatr Neurosci 12: 161\u2013164","journal-title":"Pediatr Neurosci"},{"key":"BF02252624_CR72","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00005053-198105000-00011","volume":"169","author":"M Toru","year":"1981","unstructured":"Toru M, Matsuda O, Makiguchi K, Sugano K (1981) Neuroleptic malignant syndrome-like state following withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 169: 324\u2013327","journal-title":"J Nerv Ment Dis"},{"key":"BF02252624_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000116304","volume":"26","author":"JT Turkka","year":"1987","unstructured":"Turkka JT, Myllyl\u00e4 VV (1987) Sweating dysfunction in Parkinson's disease. Eur Neurol 26: 1\u20137","journal-title":"Eur Neurol"},{"key":"BF02252624_CR74","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/0006-3223(85)90104-0","volume":"20","author":"WMA Verhoeven","year":"1985","unstructured":"Verhoeven WMA, Elderson A, Westenberg HGM (1985) Neuroleptic malignant syndrome: successful treatment with bromocriptine. Biol Psychiatry 20: 680\u2013684","journal-title":"Biol Psychiatry"},{"key":"BF02252624_CR75","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1126\/science.174.4007.408","volume":"174","author":"PF Von Voigtlander","year":"1971","unstructured":"Von Voigtlander PF, Moore KE (1971) Dopamine: release from the brain in vivo by amantadine. Science 174: 408\u2013410","journal-title":"Science"},{"key":"BF02252624_CR76","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/jcbfm.1991.110","volume":"11","author":"MA Warner","year":"1991","unstructured":"Warner MA, Neill KH, Nadler JV, Crain BJ (1991) Regionally selective effects of NMDA receptor antagonists against ischemic brain damage in the gerbil. J Cereb Blood Flow Metab 11: 600\u2013610","journal-title":"J Cereb Blood Flow Metab"},{"key":"BF02252624_CR77","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1001\/archneur.1992.00530330018007","volume":"49","author":"M Weller","year":"1992","unstructured":"Weller M, Kornhuber J (1992a) N-Methyl-D-aspartate antagonists, schizophrenia, and neuroleptic malignant syndrome. Arch Neurol 49: 900\u2013901","journal-title":"Arch Neurol"},{"key":"BF02252624_CR78","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0306-9877(92)90027-A","volume":"38","author":"M Weller","year":"1992","unstructured":"Weller M, Kornhuber J (1992b) A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. Med Hypotheses 38: 329\u2013333","journal-title":"Med Hypotheses"},{"key":"BF02252624_CR79","doi-asserted-by":"crossref","unstructured":"Weller M, Finiels-Marlier F, Paul SM (1993) NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. Brain Res (in press)","DOI":"10.1016\/0006-8993(93)90464-X"},{"key":"BF02252624_CR80","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/BF01250322","volume":"44","author":"W Wesemann","year":"1979","unstructured":"Wesemann W, Dette-Wildenhahn G, Fellehner H (1979) In vitro studies on the possible effects of 1-aminoadamantanes on the serotonergic system in M. Parkinson. J Neural Transm 44: 263\u2013285","journal-title":"J Neural Transm"},{"key":"BF02252624_CR81","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/archpsyc.1989.01810050096021","volume":"46","author":"A Wolkin","year":"1989","unstructured":"Wolkin A, Brodie JD, Barouche F, Rotrosen J, Wolf AP, Smith M, Fowler J, Cooper TB (1989) Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry 46: 482\u2013484","journal-title":"Arch Gen Psychiatry"},{"key":"BF02252624_CR82","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1176\/ajp.140.12.1619","volume":"140","author":"G Zubenko","year":"1983","unstructured":"Zubenko G, Pope HG (1983) Management of a case of neuroleptic malignant syndrome with bromocriptine. Am J Psychiatry. 140: 1619\u20131620","journal-title":"Am J Psychiatry"}],"container-title":["Journal of Neural Transmission - Parkinson's Disease and Dementia Section"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02252624.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF02252624\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02252624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02252624.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:03:02Z","timestamp":1750827782000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF02252624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,2]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1993,2]]}},"alternative-id":["BF02252624"],"URL":"https:\/\/doi.org\/10.1007\/bf02252624","relation":{},"ISSN":["0936-3076"],"issn-type":[{"value":"0936-3076","type":"print"}],"subject":[],"published":{"date-parts":[[1993,2]]},"assertion":[{"value":"23 February 1993","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 1993","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 1993","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}